CY1107724T1 - Νεα πεπτιδια - Google Patents

Νεα πεπτιδια

Info

Publication number
CY1107724T1
CY1107724T1 CY20071101137T CY071101137T CY1107724T1 CY 1107724 T1 CY1107724 T1 CY 1107724T1 CY 20071101137 T CY20071101137 T CY 20071101137T CY 071101137 T CY071101137 T CY 071101137T CY 1107724 T1 CY1107724 T1 CY 1107724T1
Authority
CY
Cyprus
Prior art keywords
amino acid
new peptides
compound
activity
replaced
Prior art date
Application number
CY20071101137T
Other languages
Greek (el)
English (en)
Inventor
Kenji Kangawa
Masayasu Kojima
Hiroshi Hosoda
Hisayuki Matsuo
Yoshiharu Minamitake
Original Assignee
Kenji Kangawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenji Kangawa filed Critical Kenji Kangawa
Publication of CY1107724T1 publication Critical patent/CY1107724T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CY20071101137T 1999-07-23 2007-08-28 Νεα πεπτιδια CY1107724T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP21000299 1999-07-23
JP33884199 1999-11-29
JP2000126623 2000-04-26
EP00946453A EP1197496B8 (en) 1999-07-23 2000-07-24 Novel peptides

Publications (1)

Publication Number Publication Date
CY1107724T1 true CY1107724T1 (el) 2013-04-18

Family

ID=27329078

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20071101137T CY1107724T1 (el) 1999-07-23 2007-08-28 Νεα πεπτιδια
CY20101100012T CY1109714T1 (el) 1999-07-23 2010-01-05 Νεα πεπτιδια

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20101100012T CY1109714T1 (el) 1999-07-23 2010-01-05 Νεα πεπτιδια

Country Status (16)

Country Link
US (5) US7385026B1 (enExample)
EP (3) EP2119785B1 (enExample)
JP (2) JP3471780B2 (enExample)
KR (1) KR100827973B1 (enExample)
CN (2) CN100506844C (enExample)
AT (2) ATE449174T1 (enExample)
AU (2) AU784035B2 (enExample)
BR (2) BRPI0012688B8 (enExample)
CA (2) CA2696819C (enExample)
CY (2) CY1107724T1 (enExample)
DE (2) DE60035502T2 (enExample)
DK (2) DK1795598T3 (enExample)
ES (3) ES2401939T3 (enExample)
IL (2) IL147652A0 (enExample)
PT (2) PT1795598E (enExample)
WO (1) WO2001007475A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100506844C (zh) 1999-07-23 2009-07-01 寒川贤治 新的肽
CA2392019A1 (en) 1999-11-22 2001-05-31 Zymogenetics, Inc. Method of forming a peptide-receptor complex with zsig33
US6897286B2 (en) 2000-05-11 2005-05-24 Zymogenetics, Inc. Zsig33-like peptides
WO2001085804A1 (fr) 2000-05-12 2001-11-15 Kaneka Corporation Procede de purification de polymere vinylique
US6967237B2 (en) 2000-05-30 2005-11-22 Merck & Co., Inc. Ghrelin analogs
AU2001283938A1 (en) * 2000-07-24 2002-02-05 Ardana Bioscience Limited Ghrelin antagonists
IL162780A0 (en) * 2002-04-11 2005-11-20 Kenji Kangawa Method for producing modified peptide
ES2615484T3 (es) * 2002-05-21 2017-06-07 Daiichi Sankyo Company, Limited Composiciones medicinales que contienen grelina
MXPA04011247A (es) * 2002-07-19 2005-02-17 Cytos Biotechnology Ag Conjugados portadores de grelina.
EP1578778B1 (en) * 2002-07-23 2011-01-26 Ipsen Pharma Ghrelin analogs
TWI331922B (en) 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
US20060128615A1 (en) * 2002-09-18 2006-06-15 Pierrette Gaudreau Ghrh analogues
EP1407779A1 (en) * 2002-10-10 2004-04-14 Gastrotech A/S Use of ghrelin for treating low body weight and body fat in gastrectomized individuals
ES2383685T3 (es) * 2003-04-30 2012-06-25 Kenji Kangawa Preventivos o remedios para hepatopatía
EP1633397A2 (en) * 2003-06-04 2006-03-15 Eli Lilly And Company Anti-ghrelin fab antibodies
WO2005026211A2 (en) * 2003-09-05 2005-03-24 Eli Lilly And Company Anti-ghrelin antibodies
CN1321131C (zh) * 2003-12-26 2007-06-13 李宁 猪Ghrelin衍生物及其编码基因与应用
CN1905903A (zh) * 2004-01-20 2007-01-31 赛托斯生物技术公司 生长素释放肽－载体偶联物
US7026175B2 (en) 2004-03-29 2006-04-11 Applied Materials, Inc. High throughput measurement of via defects in interconnects
JP2007532495A (ja) * 2004-04-07 2007-11-15 ガストロテック・ファルマ・アクティーゼルスカブ グレリン欠乏を治療するための分泌促進薬の使用
WO2005097831A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Uses of isolated binding members capable of binding specifically to secretagogues
WO2005097830A2 (en) * 2004-04-07 2005-10-20 Aditech Pharma Ab Uses of isolated binding members capable of reducing the biological activity of secretagogue compounds
EP1750745A1 (en) * 2004-05-11 2007-02-14 The United States of America, represented by the Secretary, Department of Health and Human Services Methods of inhibiting proinflammatory cytokine expression using ghrelin
WO2005120484A1 (ja) * 2004-06-09 2005-12-22 Kurume University グレリンの生理学的機能のレギュレーター
EP1776386A1 (en) * 2004-07-14 2007-04-25 Eli Lilly And Company Anti-ghrelin antibodies
WO2006045319A2 (en) * 2004-10-27 2006-05-04 Gastrotech Pharma A/S Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure
WO2006045313A2 (en) * 2004-10-27 2006-05-04 Gastrotech Pharma A/S Uses of secretagogues for treatment of organ transplant patients
JP2008521840A (ja) * 2004-11-30 2008-06-26 ガストロテック・ファルマ・アクティーゼルスカブ 成長ホルモン分泌促進物質レセプター１ａリガンド
US7803768B2 (en) 2005-02-23 2010-09-28 Kyoto University Method for treatment of hyperglycemia in a subject in need thereof
US7479271B2 (en) 2005-02-23 2009-01-20 Eli Lilly And Company Humanized anti-ghrelin antibodies
RU2427587C2 (ru) * 2005-09-28 2011-08-27 Ипсен Фарма С.А.С. Аналоги грелина
CN105381453B9 (zh) 2005-09-29 2019-01-11 益普生制药股份有限公司 用于刺激胃肠运动性的组合物和方法
US20090305969A1 (en) 2005-11-21 2009-12-10 Noboru Murakami Skin Repair Accelerating Therapeutic Agent Containing Desacyl Ghrelin and Derivatives Thereof as Active Ingredient
JPWO2007058359A1 (ja) * 2005-11-21 2009-05-07 国立大学法人 宮崎大学 グレリン及びその誘導体又はＧＨＳ−Ｒ１ａに作用する物質を有効成分とする皮膚修復促進治療剤
WO2007106385A2 (en) * 2006-03-10 2007-09-20 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment
US7981860B2 (en) 2006-03-13 2011-07-19 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation
US9675679B2 (en) * 2006-08-01 2017-06-13 The Scripps Research Institute Vaccines and methods for controlling adiposity
KR20090060291A (ko) 2006-08-11 2009-06-11 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 그렐린 및 그 유도체 또는 ＧＨＳ―Ｒ１ａ에 작용하는 물질을 유효성분으로 포함하는 척수 신경 수복 촉진 치료제
EP2070549A1 (en) * 2006-08-11 2009-06-17 University of Miyazaki Therapeutic agent for acceleration of spinal nerve repair comprising desacyl ghrelin or derivative thereof as active ingredient
WO2008039415A2 (en) 2006-09-27 2008-04-03 Ipsen Pharma S.A.S. Analogs of ghrelin substituted at the n-terminal
KR20130018965A (ko) 2008-05-23 2013-02-25 다이이찌 산쿄 가부시키가이샤 목적 펩타이드의 혈장내 반감기 연장 작용을 가진 펩타이드
CN108530543B (zh) 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
US8883721B2 (en) * 2009-05-12 2014-11-11 Mcgill University Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
EP2524697B1 (en) 2010-01-15 2016-09-21 University of Miyazaki Ghrelin for promoting recovery of animal under medical treatment
WO2011159917A2 (en) * 2010-06-16 2011-12-22 The Administrators Of The Tulane Educational Fund Growth hormone secretatogue receptor antagonists and uses thereof
US9555077B2 (en) 2011-03-03 2017-01-31 University Of Miyazaki Methods of lowering body temperature by administration of desacyl ghrelin or its derivative
JP5560248B2 (ja) * 2011-09-07 2014-07-23 花王株式会社 ジペプチド誘導体及びその製造方法
CA2865578C (en) 2012-02-27 2023-01-17 Amunix Operating Inc. Xten conjugate compositions and methods of making same
KR20220051197A (ko) 2012-05-17 2022-04-26 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어
WO2014054798A1 (ja) 2012-10-04 2014-04-10 独立行政法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
KR102499918B1 (ko) 2012-10-24 2023-02-14 다이이찌 산쿄 가부시키가이샤 근위축성 측삭 경화증 치료제
JP6143270B2 (ja) * 2013-01-31 2017-06-07 学校法人東京薬科大学 マイオスタチン阻害ペプチド
TWI662967B (zh) * 2013-03-25 2019-06-21 日商志瑞亞新藥工業股份有限公司 食後期之胃運動亢進劑
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
CN109879935B (zh) * 2019-03-04 2020-11-20 南京工业大学 一种多肽的液相合成方法
IL292863A (en) 2019-11-13 2022-07-01 Amunix Pharmaceuticals Inc Barcoded xanthan polypeptides and their compositions, and methods for their preparation and use
EP4593867A2 (en) 2022-09-30 2025-08-06 Extend Biosciences, Inc. Long-acting parathyroid hormone
CN120818010B (zh) * 2025-09-18 2025-12-05 天津科技大学 一种来自植物乳杆菌属细胞外囊泡的短肽及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
IL98910A0 (en) * 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
US5663146A (en) * 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
ATE227307T1 (de) * 1992-04-07 2002-11-15 Scripps Research Inst Verfahren zur herstellung modifizierten proteine
EP0819137A1 (en) * 1995-03-31 1998-01-21 American Cyanamid Company Peptides with growth promotion properties
IL118473A0 (en) 1995-06-02 1996-09-12 Suntory Ltd Staphylococcus aureus V8 protease genes coding therefor and a method for the production thereof
CA2198966C (en) 1996-03-04 2011-06-21 Yuji Suzuki Method for cleaving chimeric protein using processing enzyme
JP3982866B2 (ja) 1996-03-04 2007-09-26 アスビオファーマ株式会社 分泌型Ｋｅｘ２誘導体の製造方法
WO1999063088A2 (en) * 1998-06-02 1999-12-09 Genentech, Inc. Membrane-bound proteins and nucleic acids encoding the same
CA2284733C (en) 1997-03-24 2010-10-26 Zymogenetics, Inc. Motilin homologs
CN1120846C (zh) * 1999-02-13 2003-09-10 中国人民解放军军事医学科学院基础医学研究所 生长激素释放肽及其应用
US6420521B1 (en) * 1999-06-30 2002-07-16 Zymogenetics, Inc. Short gastrointestinal peptides
CN100506844C (zh) * 1999-07-23 2009-07-01 寒川贤治 新的肽

Also Published As

Publication number Publication date
ES2335235T3 (es) 2010-03-23
BRPI0012688B8 (pt) 2021-05-25
US9938332B2 (en) 2018-04-10
EP1197496A1 (en) 2002-04-17
CN101693736B (zh) 2020-09-11
JP2004000251A (ja) 2004-01-08
EP1795598B1 (en) 2009-11-18
US20090170763A1 (en) 2009-07-02
WO2001007475A1 (en) 2001-02-01
EP1197496B8 (en) 2007-10-03
AU2006201580B2 (en) 2009-01-08
BR0012688A (pt) 2002-04-16
DK1197496T3 (da) 2007-10-22
AU6023100A (en) 2001-02-13
ES2401939T3 (es) 2013-04-25
KR100827973B1 (ko) 2008-05-21
ES2288151T3 (es) 2008-01-01
ATE366813T1 (de) 2007-08-15
CA2380058A1 (en) 2001-02-01
PT1795598E (pt) 2010-01-05
IL147652A (en) 2010-04-29
DK1795598T3 (da) 2010-02-01
DE60035502D1 (de) 2007-08-23
CY1109714T1 (el) 2014-08-13
BRPI0012688B1 (pt) 2018-06-05
EP2119785A1 (en) 2009-11-18
US7385026B1 (en) 2008-06-10
AU2006201580A1 (en) 2006-05-18
US8524871B2 (en) 2013-09-03
US20110184153A1 (en) 2011-07-28
KR20020026543A (ko) 2002-04-10
CA2696819C (en) 2015-07-07
CA2380058C (en) 2011-08-09
EP1795598A1 (en) 2007-06-13
US8227570B2 (en) 2012-07-24
US20130172251A1 (en) 2013-07-04
DE60035502T2 (de) 2008-03-20
JP4227857B2 (ja) 2009-02-18
JP3471780B2 (ja) 2003-12-02
EP1197496B1 (en) 2007-07-11
ATE449174T1 (de) 2009-12-15
US9573986B2 (en) 2017-02-21
CA2696819A1 (en) 2001-02-01
EP1197496A4 (en) 2002-11-20
AU784035B2 (en) 2006-01-19
EP2119785B1 (en) 2013-03-13
CN100506844C (zh) 2009-07-01
DE60043361D1 (de) 2009-12-31
US20100240866A1 (en) 2010-09-23
CN1362968A (zh) 2002-08-07
IL147652A0 (en) 2002-08-14
CN101693736A (zh) 2010-04-14
PT1197496E (pt) 2007-08-29

Similar Documents

Publication Publication Date Title
DK1795598T3 (da) Hidtil ukendte peptider
EP1302542A4 (en) NEW, PHYSIOLOGICALLY ACTIVE PEPTIDE AND ITS USE
ATE446758T1 (de) Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
UY27585A1 (es) Cis - imidazolinas
HUP9701059A2 (hu) Stronciumsók alkalmazása ízületi bántalmak kezelésére alkalmas gyógyszerkészítmények előállítására
ATE155486T1 (de) Zyklische peptide und ihre verwendung
SI1546127T1 (sl) Novi pirimidinamidni derivati in njihova uporaba
ATE497390T1 (de) Neue therapeutische verwendung von smr-1 peptide
DE69841267D1 (de) Verwendung von r-carprofen zur Vorbeugung der Alzheimerschen Krankheit
TR200101245T2 (tr) N-arilsulfonil-aminoasit-omega-amidler
DE60231649D1 (de) Mittel zur behandlung von augentrockenheit und damit zusammenhängenden erkrankungen
DE60028928D1 (de) Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
AP9901474A0 (en) Pharmaceutical composition for treating viral diseases.
MXPA04000775A (es) Uso novedoso del 2 -[5-(4-fluorofenil) -3-piridilmetilamino-metil] -cromano y sus sales fisiologicamente aceptables.
DE60329115D1 (de) Tumorantigenprotein und dessen verwendung
WO2002062944A2 (en) Novel physiologically active peptide and use thereof
GB0207644D0 (en) Peptides and their use
AU2003202489A1 (en) Screening method
BR9711960A (pt) Verapamil como um medicamento para o tratamento de angina
YU17002A (sh) Upotreba deksrazoksana u lečenju psorijaze
NO20023783D0 (no) Partnere av PTB 1-domene av FE65, fremstilling og anvendelse derav
ATE417061T1 (de) Scorpionpeptid als blutdrucksenkendes mittel
WO2003029290A1 (en) Drug transporter and use thereof
HUP0203173A2 (hu) Metformint és N-[2-hidroxi-3-(1-piperidinil)-propoxi]-piridin-1-oxi-3-karboximidoil-kloridot tartalmazó kombinált hatóanyagos gyógyászati készítmény